RE:RE:RE:What's bringing us down ?G1945V wrote: Aducanumab keeps the Amyloid Beta hypothesis alive and well, and that helps PMN310...If not, FDA's approval will be withdrawn and that's that.
Well that's the Goldstein hypothesis anyway, and how has it worked so far?
Please consider the alternative hypothesis, where our consultants had positioned PMN as cheerleading Aducanumab's failure, qualified approval notwithstanding, same facts but reverse spin, e.g.,
It will fail because it is not selective...It did fail because it is not selective. It's not really much of a hypothesis because Goldstein recognized that this had to be done immediately after Biogen discontinued the trials, this was his headline and tag line Mar 21, 2019:
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
IMO this needs to be done again, NOW, not months from now under the direction of a new CEO. Stop trying to ride the lame horse and just shoot it!